Patents Issued in November 13, 2018
  • Patent number: 10123991
    Abstract: A therapeutic compound has a modified phenolic compound of the general formula (I) wherein at least one of R, R1, R2, R3, and R4 is an electrophilic group chosen from halogen, aldehyde, haloalkane, alkene, butyryl, flurophenol, sulfonamide, flurophenol sulfoxide and the remaining R, R1, R2, R3, and R4 is are each independently hydrogen, a hydroxyl group, an alkoxy group, a rutinosyl group, a carboxyl group, chromone, benzopyran, a rhamnosyl group, a substituted alkoxy group or a substituted acyloxy group wherein the substituent is chosen from hydroxyl, alkoxy, aryloxy, phenyl, halogen, and amido group. The compound can be used in a therapeutic treatment of inflammatory related diseases and condition.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: November 13, 2018
    Assignee: GLOBAL BIOLIFE INC.
    Inventor: Daryl Lee Thompson
  • Patent number: 10123992
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 13, 2018
    Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 10123993
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: November 13, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Doree F. Sitkoff, Navnath Dnyanoba Yadav, Mandar Shrikrishna Bodas, Rajeev S. Bhide, Sharanabasappa Patil, Kumaresan Chinnakotti, Prasanna Savanor Maddu Rao, Jeevan Prakash Shetty
  • Patent number: 10123994
    Abstract: A compound of formula: or its pharmaceutically acceptable salt. L is NR2R3, SR7, SO2R8, alkyl, or alkenyl; R2 is hydrogen, alkyl, alkenyl, or alkynyl; R3 is hydrogen, alkyl, alkenyl, alkynyl; R7 is hydrogen, alkyl, alkenyl, or alkynyl; R8 is hydrogen, alkyl, alkenyl, or alkynyl, provided that R8 is not unsubstituted methyl or trifluoromethyl; Y is alkyl, alkenyl, alkynyl, aryl, provided that Y is not unsubstituted methyl or unsubstituted ethyl; Z is —CR6?, or —N?; R1 is hydrogen, or alkyl; R4, R5 and R6 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkenyl, or alkynyl.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 13, 2018
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Eiichi Kojima, Yu Hinata, Toshihiro Wada
  • Patent number: 10123995
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: November 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Eric Mertz, Weiguo Liu, Scott D. Edmondson, Amjad Ali, Ying-Duo Gao, Santhosh F. Neelamkavil, Sung-Sau So, Remond Moningka, Wanying Sun, Alan Hruza, Linda L. Brockunier
  • Patent number: 10123996
    Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: November 13, 2018
    Assignee: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Patent number: 10123997
    Abstract: A method of treating hepatitis B virus includes inhibiting the activities of AKT and/or mTOR, inhibiting the synthesis of 5-phosphate ribose, and inhibiting HBV DNA and HBV cccDNA.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: November 13, 2018
    Inventor: Yong Liao
  • Patent number: 10123998
    Abstract: The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: November 13, 2018
    Assignee: Plexxikon Inc.
    Inventors: Gideon Bollag, Klaus-Peter Hirth, Prabha N. Ibrahim, Paul Lin, Brian West
  • Patent number: 10123999
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, Cl, or X2 is H, Br, Cl, or n1 is 1-2; and n2 is 1-2.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: November 13, 2018
    Assignee: Exelixis, Inc.
    Inventor: Jo Ann Wilson
  • Patent number: 10124000
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: November 13, 2018
    Assignee: SARCODE BIOSCIENCE INC.
    Inventors: Wang Shen, Kenneth Barr, Johan D. Oslob, Min Zhong
  • Patent number: 10124001
    Abstract: Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-?) for inhibiting the growth of PKC-?-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: November 13, 2018
    Assignee: University of Canberra
    Inventors: Sudha Rao, Anjum Zafar
  • Patent number: 10124002
    Abstract: The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: November 13, 2018
    Assignee: Purdue Pharma, L.P.
    Inventors: Jay Jie-Qiang Wu, Ling Wang
  • Patent number: 10124003
    Abstract: The problem to be solved by the present invention is to provide an anticancer agent for treating tumors resistant to other antitumor agents that inhibit FGFR, and a method for treating such tumors. The present invention provides an antitumor agent for administration to a tumor patient resistant to an FGFR inhibitor, the antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) below or a salt thereof. The present invention also provides a therapeutic method using the anticancer agent.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: November 13, 2018
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventor: Hiroshi Sootome
  • Patent number: 10124004
    Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 13, 2018
    Assignee: Teijin Pharma Limited
    Inventors: Tsuyoshi Mizuno, Tomohiro Shimada, Gen Unoki, Masaru Ebisawa, Susumu Takeuchi, Kunio Minamizono, Kosuke Sasaki, Takuya Yokosaka, Junji Igarashi, Akinobu Maruyama, Hiroshi Takahashi, Kyohei Horie, Yuri Sakai
  • Patent number: 10124005
    Abstract: Migraine is a multi-symptom disease involving pain; histamine triggers; and nausea with or without vomiting. Current over-the-counter medications focus only on treating pain. This invention involves treating other common triggers and symptoms as well as pain. Acetaminophen and caffeine are already being used but the addition of meclizine is what makes this medication my invention. The addition of meclizine covers the other symptoms that make migraine sufferers miserable which is nausea/vomiting and treats the possible histamine mediated trigger of migraines because it has antihistaminic properties. As a migraine sufferer myself, I experience all of these symptoms and would very much like to have everything I need to cover these debilitating symptoms in one medication hence my invention.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: November 13, 2018
    Inventor: Lisa Josette Myslinski
  • Patent number: 10124006
    Abstract: The present invention is directed to compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. In particular, embodiments of the present invention relate to the use of Sigma-1 receptor agonists for use in the treatment or prevention of progressive fibrosis characterized by the overproliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1-receptor agonists are disclosed.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: November 13, 2018
    Assignees: MTA Tämogatott Kutatócsoportok Irodája, Semmelweis Egyetem
    Inventors: Andrea Fekete, Ádám Vannay
  • Patent number: 10124007
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being a pharmaceutically acceptable salt of radium 223. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer with bone metastases.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: November 13, 2018
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ningshu Liu, Arne Scholz, Andrea Hägebarth
  • Patent number: 10124008
    Abstract: A method of treating retinal diseases is disclosed that includes the step of administering an effective amount of a composition including an ASMase inhibitor to a retinal disease patient, wherein at least one disease symptom is either lessened or progression of the symptom is delayed.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 13, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Aparna Lakkaraju, Kimberly A. Toops, Li Xuan Tan
  • Patent number: 10124009
    Abstract: The present invention relate to bromodomain inhibitor compounds, pharmaceutical compositions comprising the bromodomain inhibitor compounds and methods of treating a disorder responsive to fee modulation of a BET family polypeptide using the compounds and pharmaceutical compositions described.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 13, 2018
    Assignee: Tensha Therapeutics, Inc.
    Inventors: Steven B. Landau, Michael Kagey
  • Patent number: 10124010
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 13, 2018
    Assignee: MindImmune Therapeutics, Inc.
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • Patent number: 10124011
    Abstract: An active agent for use in a method of, or for use in the preparation of a medicament for, treating or inhibiting the development of erectile dysfunction and/or incontinence following pelvic radiation treatment in a subject in need thereof, comprising administering said subject an active agent in a treatment effective amount, is described. The active agent has the general structure of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: November 13, 2018
    Assignees: BioMimetix JV, LLC, National Jewish Health
    Inventors: James D. Crapo, Rebecca Oberley Deegan
  • Patent number: 10124012
    Abstract: Provided is a method of treating metabolic diseases including type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia, obesity, hepatic steatosis, and hyperinsulinemia in a subject in need, including the step of administering to the subject a therapeutically effective amount of antcin K. Also provided is a method of enhancing protein expression ratio of phospho-5? adenosine monophosphate-activated protein kinase (phospho-AMPK) to total AMPK in skeletal muscle or liver of a subject, and a method of reducing blood leptin in a subject. Antcin K exerts prominent antidiabetic and antihyperlipidemic effects through regulation of membrane GLUT4, AMPK, Akt PPAR?, FAS, and PPAR? protein expressions and G6Pase, DGAT2, SREBP-1c, aP2, apoCIII, SREBP2, and PPAR? mRNA expressions.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: November 13, 2018
    Inventor: Chun-Ching Shih
  • Patent number: 10124013
    Abstract: Method and composition for treating psoriasis and other skin disorders.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: November 13, 2018
    Assignee: ANAPLASI PHARMACEUTICALS, LLC
    Inventor: Edward Richard Yuhas
  • Patent number: 10124014
    Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: November 13, 2018
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Sean M. Johnston, Robert D. Arbeit, Thomas J. Bigger, Dennis P. Molnar, S. Ken Tanaka
  • Patent number: 10124015
    Abstract: The disclosure describes a composition comprising a lipidaceous carrier and a peptide complex formed from poly-L-lysine or a salt thereof; and either poly-L-glutamic acid or poly-L-aspartic acid, or a salt thereof. The composition can be used to prevent or treat a disease related to pulmonary surfactant dysfunction, such as hyaline membrane disease (HMD), respiratory distress syndrome (RDS), hydrocarbon poisoning, near-drowning, HIV/AIDS-related lung diseases, adult respiratory distress syndrome (ARDS) or acute lung injury (ALI), asthma, tuberculosis (TB) or severe acute respiratory syndrome (SARS). Alternatively, the composition can be used to increase the permeability of a pharmaceutical compound or composition across a membrane of a subject or to act as a carrier. The poly-L-lysine or salt thereof is longer than the poly-L-glutamic acid or poly-L-aspartic acid so that the complex that forms has a charge-neutralized region and a positively-charged region.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: November 13, 2018
    Assignee: Stellenbosch University
    Inventors: Johann Martin Van Zyl, Johan Smith, Arthur Owen Hawtrey, Pieter Van Der Bijl
  • Patent number: 10124016
    Abstract: Disclosed is a nutritional composition comprising a combination of non-digestible oligosaccharides and a product obtained by incubating an aqueous substrate by bifidobacteria and optionally a product obtained by incubating an aqueous substrate by S. thermophilus. Said combination synergistically improves the immune system by stimulating the Th1 response, and/or decreasing the Th2 response, improving the vaccination response, improving the resistance against infections and/or decreasing allergy.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 13, 2018
    Assignee: N.V. NUTRICIA
    Inventors: Belinda Potappel-Van 'T Land, Leon Matthieu Johannes Knippels, Alma Jildou Nauta, Johan Garssen
  • Patent number: 10124017
    Abstract: The present invention discloses a new use of ginsenoside M1 for treating or preventing gout.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: November 13, 2018
    Inventors: Sheau-Long Lee, Yu-Chieh Lee, Kuo-Feng Hua
  • Patent number: 10124019
    Abstract: The invention is directed to compositions that function to remove cholesterol from a mammal suffering from an elevated cholesterol level. The composition includes a polysaccharide having attached thereto at least one cyclic oligosaccharide. In a particular embodiment, the foregoing composition further includes at least one cell-targeting agent. The invention is also directed to methods that utilize these compositions for removing or reducing cholesterol and other lipids in a mammal suffering from an elevated level of cholesterol and/or other lipid.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: November 13, 2018
    Assignee: Cornell University
    Inventors: Frederick Maxfield, J. David Warren
  • Patent number: 10124020
    Abstract: A comestible article is disclosed that employs finely ground demulcent particles of a median particle size such that the demulcent is not readily perceived by the human tongue and in which the demulcent granules are not fully hydrated. As a result of the small particle size and lack of being fully hydrated during production, the demulcent particles exhibit faster and greater levels of hydration upon consumption, leading to quicker and more complete relief.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: November 13, 2018
    Assignee: THE HERSHEY COMPANY
    Inventors: Robert J. Huzinec, Gagan Mongia, Mahesh Venkatachalam, Thomas J. Carroll, Jordana Langiotti Swank, Pamela Gesford
  • Patent number: 10124021
    Abstract: Disclosed are intravenous hypertonic electrolyte solutions for treating intracranial hypertension while reducing the risk of inducing hyperchloremic metabolic acidosis. The solutions are characterized by a ratio of sodium-to-chloride (Na:Cl) ions of 1.2-1.6 and a total osmolarity of 310-400 mEq/L for a maintenance solution, and a total osmolarity greater than 1000 mEq/L for an initiation solution.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: November 13, 2018
    Inventor: Andrew L. Gostine
  • Patent number: 10124022
    Abstract: Methods for treating cancers, tumors, and neoplasms using a composition comprising one or more generally regarded as safe (GRAS) compounds selected from the group of components consisting of vitamins, selenium, fatty acids, fatty acid salts, and fatty acid esters, and mixtures of two or more said components, either as a stand-alone treatment or in combination with one or more anti-cancer drugs or devices or other anti-neoplastic agents, treatments, or devices are provided. In some instances, concomitant hyperthermia therapy is employed. Also provided are compositions and kits containing the compositions, for implement various aspects of the invention.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: November 13, 2018
    Assignee: ChemoTherapeutics, LLC
    Inventors: Gary Keeling, Keith B. Hoffman
  • Patent number: 10124023
    Abstract: The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARS), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhances immune-activating properties.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: November 13, 2018
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Renier J. Brentjens, Hollie J. Jackson
  • Patent number: 10124024
    Abstract: Disclosed herein are methods of terminally sterilizing bacterial minicells or compositions comprising bacterial minicells by exposure to ionizing irradiation. Also disclosed are terminally sterilized bacterial minicells, pharmaceutical compositions comprising the bacterial minicells, and methods of use the bacterial minicells and pharmaceutical compositions.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: November 13, 2018
    Assignee: Vaxiion Therapeutics, LLC
    Inventors: Matthew J. Giacalone, Gary H. Ward
  • Patent number: 10124025
    Abstract: Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, B. thetaiomtaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecalis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: November 13, 2018
    Assignee: California Institute of Technology
    Inventors: Elaine Hsiao, Sara McBride, Sarkis K. Mazmanian, Paul H. Patterson
  • Patent number: 10124026
    Abstract: The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or “tourists.” The composition according to the invention contains at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus acidophilus I-1492, Lactobacillus casei and a mixture of thereof.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: November 13, 2018
    Assignee: BIO-K PLUS INTERNATIONAL, INC.
    Inventor: Francois-Marie Luquet
  • Patent number: 10124027
    Abstract: The present invention provides methods of designing panels of bacteriophages as therapeutic compositions against bacterial infections. The present invention also provides panels of bacteriophages for use in the prevention or treatment of bacterial infections.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: November 13, 2018
    Assignee: BIOCONTROL LIMITED
    Inventors: David Harper, Katy Blake
  • Patent number: 10124028
    Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: November 13, 2018
    Assignee: PSIOXUS THERAPEUTICS LIMITED
    Inventors: Brian Robert Champion, Alice Claire Noel Brown
  • Patent number: 10124029
    Abstract: A new use or method of use of a thylakoid extract, for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Also described is a method for treating or preventing a disease or disorder involving the formation of reactive oxygen species inflammation in an individual, which comprises the step of orally administering an effective dose of a thylakoid extract. Also described is an oral composition comprising purified thylakoids and a carrier for oral ingestion or oral administration, with the proviso that the carrier does not essentially consist of water, physiological saline or propylene glycol. The thylakoid extract or composition is also provided as a food or a food supplement or as a pellet, or encapsulated granules or powder.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: November 13, 2018
    Assignee: GROUPE SANTÉ DEVONIAN
    Inventors: Marc Purcell, Rejean Drouin
  • Patent number: 10124030
    Abstract: An active constituent complex includes an active carrier, an anti-inflammatory agent, a collagen synthesis enhancer, an anti-wrinkle agent, and a keratinocyte growth factor stimulant. The active constituent complex may be incorporated into a skincare composition, such as for topical application to human skin, for promoting skin repair and restructure, and for treating skin conditions.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: November 13, 2018
    Assignee: KARYNG, LLC
    Inventors: Susan Goldsberry, Karyn Grossman
  • Patent number: 10124031
    Abstract: Provided is a functional composition for preventing an Alzheimer's disease, in which the composition includes heat-treated salt that is heat-treated at 800° C. to 1200° C. as an effective component and other pharmaceutically or sitologically acceptable components. The composition can prevent an Alzheimer's disease by effectively blocking the cause path of an Alzheimer's disease in a human body.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: November 13, 2018
    Assignee: MOKPO NATIONAL UNIVERSITY INDUSTRY-ACADEMIA COOPERATION GROUP
    Inventors: Kyung Sik Ham, Jeong Yong Cho, Promyo Kitiong, Sun Young Park, JinRui Zhu
  • Patent number: 10124032
    Abstract: The present invention relates to a seven-star tea without excipient comprising Coicis Semen, Oryzae Fructus Germinatus, Triticum Aestivum, Herba Lophatheri, Fructus Crataegi, Ramulus Uncariae Cum Uncis, Periostracum Cicadae and Radix Et Rhizoma Glycyrrhizae, wherein the Triticum Aestivum is used as a forming agent in the seven-star tea, and methods for the preparation thereof. The seven-star tea of the present invention is specially suitable for children, since it has the effects of promoting appetite and removing food stagnation, clearing heat and arresting convulsion, and long-term intake of sucrose or other excipients which are not beneficial for their health is avoided.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: November 13, 2018
    Assignee: Eu Yan Sang International Ltd
    Inventors: Suet Ying Wong, Kim Wu, Kuen Kuen Ella Lee
  • Patent number: 10124033
    Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: November 13, 2018
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
  • Patent number: 10124034
    Abstract: The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: November 13, 2018
    Assignee: LEUKOLECT AS
    Inventors: Bernt Th. Walther, Mirushe Miftari
  • Patent number: 10124035
    Abstract: The invention relates to methods of treating neurological disorders in a subject, by activating a DISC1 pathway. Methods of promoting neurogenesis in adult neural progenitor cells, enhancing nerve generation and treating GSK3 disorders as well as related compositions are also provided.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: November 13, 2018
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Li-Huei Tsai, Yingwei Mao, Jon Madison, Stephen J. Haggarty
  • Patent number: 10124036
    Abstract: Liquid metabolic formulas for dietary management of tyrosinemia, including nutritional formulas and hydration beverages (sport drinks).
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: November 13, 2018
    Assignee: Cambrooke Therapeutics, Inc.
    Inventors: Charles E. Sizer, Kurt Olson, Susan Gingrich
  • Patent number: 10124037
    Abstract: The invention provides for methods for treating an inflammatory disease of the digestive system in a subject by administering a trefoil family molecule. The invention provides for methods for treating a digestive system cancer in a subject by administering a trefoil family molecule. The invention provides for methods for cell proliferation in a subject by administering a trefoil family molecule.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 13, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Timothy C. Wang, Jan K. Kitajewski
  • Patent number: 10124038
    Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: November 13, 2018
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventors: Stephen J. Elliman, Laura Rose Barkley, Jack Kavanaugh
  • Patent number: 10124039
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: November 13, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Patent number: 10124040
    Abstract: A method for crystallizing insulin or insulin analogs under alkaline conditions in the presence of zinc, purifying the crystals by filtering through a filter, and drying the crystals captured on the filter to produce crystalline insulin or insulin analog compositions is described. Method has been exemplified with insulin lispro.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: November 13, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Douglas S. Watson, Allison C. Ortigosa, Mark C. Sleevi, Kathryn M. Story
  • Patent number: 10124041
    Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding a factor VIII protein, wherein a B domain portion of the factor VIII protein is encoded by a nucleotides sequence between 90 and 111 nucleotides in length and has an amino acid sequence that is at least 85% identical to SEQ ID NO: 4 which comprises six asparagine residues. Also provided is a factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating Haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: November 13, 2018
    Assignees: UCL BUSINESS PLC, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Jenny McIntosh, Edward Tuddenham, Andrew Davidoff